Get notified when SUPN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Asset Impairment (new) — The company recorded a $54.9 million non-cash intangible asset impairment charge for APOKYN in Q2 2026, reflecting significant commercial deterioration as sales fell 51% year-over-year.
Supernus reports 32% Q2 revenue growth, raises 2026 guidance, announces merger with Indivior
Filed August 3, 2026 · Period ending August 3, 2026 · ~1 min read
Key Changes
-
high
Q2 2026 revenues rose 32% to $219.1M driven by growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO), but company posted $58.4M net loss ($1.01/share) vs. $22.5M profit in Q2 2025 due to $54.9M APOKYN impairment charge and higher SG&A.
Item 2.02 verify on EDGAR → -
high
Entered definitive agreement for all-stock merger of equals with Indivior Pharmaceuticals to create diversified CNS biopharmaceutical company; transaction subject to stockholder and regulatory approvals.
Item 2.02 verify on EDGAR → -
high
Raised full-year 2026 revenue guidance to $860-890M (from $840-870M) and adjusted operating earnings to $150-180M (from $140-170M) on stronger growth product performance.
Exhibit 99.1 view on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRS 10-Q) is open in full — no account needed.
Partner
Trade SUPN commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 4, 2026 · How we verify